Imunomodulatorji pri zdravljenju malignega melanoma

Abstract

Keywords

Data

Language:	Slovenian
Year of publishing:	2013
Typology:	1.03 - Short Scientific Article
Organization:	OI - Institute of Oncology
UDC:	616.5
COBISS:	1682043
ISSN:	1408-1741
Parent publication:	Onkologija
Views:	2265
Downloads:	580
Average score:	0 (0 votes)
Metadata:

Other data

Secondary language:	English
Secondary title:	Imunomodulators in the treatment of malignant melanoma - case report
Secondary abstract:	The incidence of melanoma is increasing, both in Slovenia and world-wide, more than any other form of cancer. According to the Cancer Registry of Slovenia, 415 patients were diagnosed with this disease in 2009 (1). Surgical removal of skin melanoma is the primary curative treatment for patients with early-stage disease. There are approximately 80% of such patients. In high-risk patients (around 10%), we also recommend treatment with high doses of interferon-α2b (2, 3). Metastatic melanoma is still an incurable disease with a 5-year survival of less than 5%. However, the prognosis for these patients has improved in the last few years, thanks to new developments in the field of systemic treatment. Besides standard treatment with systemic chemotherapy, new registered medicines are now also available with a different mechanism of action than chemotherapy, such as immunotherapy with the monoclonal antibody ipilimumab, BRAF inhibitors vemurafenib and dabrafenib, and MEK inhibitors (2, 3).
URN:	URN:NBN:SI
Pages:	str. 139-142, 158
Volume:	ǂLetn. ǂ17
Issue:	ǂšt. ǂ2
Chronology:	dec. 2013
ID:	10957274